Healthcare Professionals

Biosensors International Announces Enrollment of First Patient in Pivotal Trial of New Coronary Microcatheter - "BIOMICS".

April 05, 2022 | News | Microcatheter

The BIOMICS study is a prospective, multi-center evaluation of the safety and effectiveness of the Biosensors Microcatheter in patients undergoing Percutaneous Coronary Intervention (PCI) for the treatment of chronic total occlusions (CTO).

BIOSENSORS INTERNATIONAL ANNOUNCES ENROLLMENT OF FIRST PATIENT IN NEW SEMI-COMPLIANT BALLOON TRIAL “RISE SC STUDY".

February 04, 2022 | News | Drug-eluting Balloons

This ongoing trial will evaluate the performance of the new RISETM SC balloon which will complete the Biosensors International balloon portfolio.

The primary endpoint of BIO-RISE CHINA was presented at TCT 2021 Late Breaking Trials

November 21, 2021 | News | Bio-Rise China

This first-in-human study assessed the safety and efficacy of a Biolimus A9™ coated balloon and showed excellent results in small vessels with 0.16 mm late loss at 9 months.

TWO-YEAR RESULTS FROM THE BIOMATRIX ALPHA REGISTRY PUBLISHED IN JOURNAL OF INTERVENTIONAL CARDIOLOGY

April 29, 2021 | News | BioMatrix Alpha

MACE 7.2% Cardiac Death 1.3% MI 2.8% & ST 1.1%.

CE Mark Approval for Biolimus A9™ Coated Cobalt Chromium Coronary Stent System BioFreedom™ Ultra

October 19, 2020 | News | BioFreedom™ Ultra

BioFreedom™ Ultra is Biosensors International new, novel thin strut CoCr polymer and carrier-free Drug Coated Stent with Biosensors proprietary limus BA9™, a highly lipophilic anti-restenotic drug, developed specifically for use in coronary vascular applications. BioFreedom™ Ultra successfully extends the LEADERS FREE legacy in LEADERS FREE III.

INNOVATIVE TECHNOLOGIES

11881-000-EN - Rev.04

CAUTION: Please note that the following pages are exclusively reserved for Health Care Professionals in countries with applicable health authority product registrations. To the extent this site contains information intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions. Please contact your Biosensors International representative for availability or the products and registration status.

The law restricts these devices to sale by or on the order of a physician. Prior to use, it is important to read the "Instructions for Use" supplied with these devices for indications, contraindications, suggested procedures, warnings, and precautions.

Biosensors’ interventional cardiology products, including BioMatrix NeoFlex™, BioMatrix™ Alpha, BioFreedom™, BioFreedom™ Ultra, BMX-J® and RISE™ NC, are not available for sale in the United States and certain other countries. ALLEGRA™ is a product of NVT GmbH. Blue Sail Medical Co., Ltd is the ultimate parent company of NVT GmbH and Biosensors International Group, Ltd. and its subsidiaries are collaborating for the commercialization of the ALLEGRA™ device.

BioMatrix NeoFlex, BioMatrix Alpha, BioFreedom, BioFreedom Ultra, BMX-J, Juno, S-Stent and Rise NC are trademarks or registered trademarks of Biosensors International Group, Ltd. ALLEGRA is a trademark or registered trademark of NVT AG. All other cited trademarks are the property of their respective owners.